Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mivavotinib in R/R DLBCL
NCT03123393Phase 2Terminated
- Sponsor
- Calithera Biosciences
- Start
- Oct 2017
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label trial of mivavotinib in diffuse large B-cell lymphoma (DLBCL) (2 cohorts), sponsored by Calithera Biosciences. Primary endpoint: Overall Response Rate up to 12 months. Started Oct 2017; status: terminated.
02
Drugs
mivavotinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03123393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03123393.